Currently in various stages of development are 63 drugs targeting SCN11A (most unspecific blockers of all Nav subtypes), with 341 indications, including headache, epilepsy and pain in general (https://genetics.opentargets.org/gene/ENSG00000168356). The gene discussed is SCN11A; the disease is epilepsy.